caffeine and Cirrhosis, Liver studies

Research Excerpts

Excerpt	Relevance	Reference
"Our meta-analysis demonstrated that caffeine intake is significantly associated with decreased odds of advanced hepatic fibrosis in patients with chronic hepatitis C."	8.95	Effects of caffeine consumption in patients with chronic hepatitis C: A systematic review and meta-analysis. ( Jaruvongvanich, V; Klomjit, N; Sanguankeo, A; Upala, S, 2017)
"Role of caffeine consumption in chronic hepatitis B virus (HBV)-infected patients and the interaction with alcohol consumption is unclear."	7.77	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. ( Chan, HL; Ong, A; Wong, GL; Wong, VW, 2011)
"To determine the utility of the 13C-caffeine breath test in chronic hepatitis B virus and its ability to monitor response to lamivudine."	7.73	The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. ( Jones, DB; Katelaris, PH; Le Couteur, DG; Lin, BP; Ngu, MC; Park, GJ; Seow, F, 2005)
"To evaluate the effect of the consumption of caffeine-containing beverages on the risk of symptomatic liver cirrhosis (LC)."	7.71	Coffee, caffeine, and the risk of liver cirrhosis. ( Bagnardi, V; Corrao, G; D'Amicis, A; Klatsky, A; Zambon, A, 2001)
"The study group consisted of 7 patients with compensated liver cirrhosis and 10 healthy volunteers, all individuals were given a single 280 mg dose of caffeine perorally."	7.71	[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ( Perlík, F; Pucelíková, T; Slanar, O, 2001)
"Apparent pharmacokinetic parameters of caffeine elimination from the circulation were determined in 27 patients with histologically confirmed liver cirrhosis, 8 patients with miscellaneous liver disease, and 8 patients with other than liver disease."	7.67	Correlation of caffeine elimination and Child's classification in liver cirrhosis. ( Gerok, W; Haag, K; Holstege, A; Staiger, M, 1989)
"The caffeine clearance was determined using two caffeine concentrations from blood samples taken at 2 p."	6.68	Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ( Lee, SD; Lo, KJ; Lu, RH; Shyu, JK; Wang, YJ, 1996)
"The patients with liver cirrhosis were classified according to the Child--Pugh scoring system."	6.68	[Diagnostic value of the study of caffeine elimination in chronic liver diseases]. ( Bariska, J; Darnót, G; Nemesánszky, E, 1995)
"The pooled OR of advanced liver fibrosis in HCV-infected patients who consumed caffeine on a regular basis versus those who did not was 0."	6.55	Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis. ( Thongprayoon, C; Ungprasert, P; Wijarnpreecha, K, 2017)
"Hepatitis C is considered the major cause of cirrhosis and hepatocellular carcinoma."	5.42	Caffeine inhibits hepatitis C virus replication in vitro. ( Batista, MN; Braga, AC; Carneiro, BM; Rahal, P, 2015)
"The association of CC with nonalcoholic fatty liver disease (NAFLD) has not been established."	5.38	Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. ( Calcagno, CJ; Harrison, SA; Jones, FJ; Molloy, JW; Torres, DM; Williams, CD, 2012)
"The CBT was applied to 48 patients with NAFLD."	5.37	Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. ( Fung, C; George, J; Katelaris, PH; Ngu, MC; Park, GJ; Seow, F; Wiseman, E, 2011)
" These findings suggest that CA pharmacokinetic parameters can be estimated using a simplified three-point blood sampling procedure following a single oral load and that the serum PX/CA or (PX + TB + TP)/CA ratio in a single blood sample taken 2 or 4 h after dosing provides a useful indicator for the assessment of hepatic drug-oxidizing capacity, N-demethylation, in decompensated liver cirrhosis."	5.28	A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. ( Fukao, K; Ishikawa, A; Iwasaki, Y; Misawa, S; Osada, A; Tanaka, E; Tsuji, K; Yamamoto, Y, 1992)
"Sixteen patients not infected with hepatitis B virus or human immunodeficiency virus who had hepatic impairment due to liver cirrhosis were assigned to moderately or severely impaired groups by clinical signs/symptoms, 14C-aminopyrine metabolic activity and caffeine clearance and compared with eight healthy controls."	5.08	The pharmacokinetics of lamivudine in patients with impaired hepatic function. ( Breuel, P; Horak, J; Johnson, MA, 1998)
"Our meta-analysis demonstrated that caffeine intake is significantly associated with decreased odds of advanced hepatic fibrosis in patients with chronic hepatitis C."	4.95	Effects of caffeine consumption in patients with chronic hepatitis C: A systematic review and meta-analysis. ( Jaruvongvanich, V; Klomjit, N; Sanguankeo, A; Upala, S, 2017)
" We used a combination of the keywords "coffee", "caffeine", "tea", "non-alcoholic fatty liver disease", "non-alcoholic steatohepatitis", "metabolic syndrome"."	4.93	Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. ( Del Rio, D; Godos, J; Grosso, G; Marventano, S; Mistretta, A; Pluchinotta, F; Salomone, F, 2016)
"We assessed the pharmacokinetics of the six compounds and their CYP-specific metabolites of the Basel phenotyping cocktail (CYP1A2: caffeine, CYP2B6: efavirenz, CYP2C9: flurbiprofen, CYP2C19: omeprazole, CYP2D6: metoprolol, CYP3A: midazolam) in patients with liver cirrhosis (n = 16 Child A cirrhosis, n = 15 Child B cirrhosis, n = 5 Child C cirrhosis) and matched control subjects (n = 12)."	4.12	Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently. ( Bachmann, F; Bouitbir, J; Duthaler, U; Grandinetti, T; Haschke, M; Hruz, P; Krähenbühl, S; Pfefferkorn, F; Suenderhauf, C, 2022)
"Coffee or caffeine has been proposed to protect against hepatic fibrosis, but few data are available on their effects in patients with chronic hepatitis C virus (HCV) infection."	3.81	Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. ( El-Serag, HB; Kanwal, F; Khalaf, N; Kuzniarek, J; Mittal, S; Ramsey, D; Tavakoli-Tabasi, S; White, D, 2015)
"Role of caffeine consumption in chronic hepatitis B virus (HBV)-infected patients and the interaction with alcohol consumption is unclear."	3.77	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. ( Chan, HL; Ong, A; Wong, GL; Wong, VW, 2011)
"To determine the utility of the 13C-caffeine breath test in chronic hepatitis B virus and its ability to monitor response to lamivudine."	3.73	The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. ( Jones, DB; Katelaris, PH; Le Couteur, DG; Lin, BP; Ngu, MC; Park, GJ; Seow, F, 2005)
"To evaluate the effect of the consumption of caffeine-containing beverages on the risk of symptomatic liver cirrhosis (LC)."	3.71	Coffee, caffeine, and the risk of liver cirrhosis. ( Bagnardi, V; Corrao, G; D'Amicis, A; Klatsky, A; Zambon, A, 2001)
"The study group consisted of 7 patients with compensated liver cirrhosis and 10 healthy volunteers, all individuals were given a single 280 mg dose of caffeine perorally."	3.71	[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ( Perlík, F; Pucelíková, T; Slanar, O, 2001)
"In an exploratory study the 24-h urinary excretion pattern of caffeine and 14 of its major metabolites was studied in 32 volunteers (adults, adolescents and children), 14 patients either with end stage renal disease or liver cirrhosis, 7 heavy smokers and 27 patients on therapy with cimetidine, allopurinol, theophylline or phenytoin."	3.68	Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations. ( Bircher, J; Brandes, A; Compagnone, D; Hille, H; Münch, B; Ullrich, D, 1992)
"Caffeine elimination was studied in 419 patients with cirrhotic and noncirrhotic liver disease of different etiology (hepatitis B virus infection n = 79; hepatitis NANB virus infection n = 74; ethanol-induced liver damage n = 143; primary biliary cirrhosis I-IV n = 63; cryptogenic liver cirrhosis n = 60) following oral administration of 366 mg caffeine."	3.68	Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology. ( Brachtel, D; Gallenkamp, H; Hofstetter, G; Joeres, R; Klinker, H; Richter, E; Zilly, W, 1993)
"Fasting plasma caffeine concentration and various parameters of caffeine elimination from plasma obtained after a standardized oral dose of 140 mg caffeine have been compared in nine patients with liver cirrhosis, eight patients with non-cirrhotic liver disease and ten healthy volunteers with regard to their ability to discriminate between the different groups."	3.67	Caffeine elimination: a test of liver function. ( Kleber, G; Paumgartner, G; Stellaard, F; Wang, T, 1985)
"Apparent pharmacokinetic parameters of caffeine elimination from the circulation were determined in 27 patients with histologically confirmed liver cirrhosis, 8 patients with miscellaneous liver disease, and 8 patients with other than liver disease."	3.67	Correlation of caffeine elimination and Child's classification in liver cirrhosis. ( Gerok, W; Haag, K; Holstege, A; Staiger, M, 1989)
"Caffeine clearance has been determined in 117 volunteers and patients (including 27 patients with liver cirrhosis) after oral application of 366."	3.67	[One point determination of oral caffeine clearance in patients with liver diseases]. ( Brachtel, D; Epping, J; Hofstetter, G; Joeres, R; Junggeburth, J; Klinker, H; Richter, E; Zilly, W, 1988)
"Subjects with liver cirrhosis and chronic hepatitis, as well as healthy volunteers, were given the oral dose of 300 mg caffeine."	2.71	Serum metabolite/caffeine ratios as a test for liver function. ( Flieger, J; Jodynis-Liebert, J; Juszczyk, J; Matuszewska, A, 2004)
"Caffeine elimination was studied in 73 patients admitted to an intensive care unit, 33 of whom had liver disease."	2.68	Caffeine test assessment for measuring liver function in critically ill patients. ( Calatayud, O; Ibáñez, P; Rodríguez, M; Sánchez-Alcaraz, A, 1995)
"The caffeine clearance was determined using two caffeine concentrations from blood samples taken at 2 p."	2.68	Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ( Lee, SD; Lo, KJ; Lu, RH; Shyu, JK; Wang, YJ, 1996)
"Caffeine in hair was identified and measured by gas chromatography-mass spectrometry after digestion of the hair matrix with protease and extraction of the caffeine with chloroform."	2.68	The measurement of caffeine concentration in scalp hair as an indicator of liver function. ( Gotoh, S; Katoh, E; Mizuno, A; Nakashima, M; Uematsu, T, 1996)
"The patients with liver cirrhosis were classified according to the Child--Pugh scoring system."	2.68	[Diagnostic value of the study of caffeine elimination in chronic liver diseases]. ( Bariska, J; Darnót, G; Nemesánszky, E, 1995)
"The pooled OR of advanced liver fibrosis in HCV-infected patients who consumed caffeine on a regular basis versus those who did not was 0."	2.55	Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis. ( Thongprayoon, C; Ungprasert, P; Wijarnpreecha, K, 2017)
" It is currently unknown whether these protective effects are related to caffeine (CAF), or to its combination with other common and/or highly bioavailable coffee compounds, such as trigonelline (TRI) and chlorogenic acid (CGA)."	1.56	The combination of coffee compounds attenuates early fibrosis-associated hepatocarcinogenesis in mice: involvement of miRNA profile modulation. ( Barbisan, LF; Cogliati, B; da Silva, TC; Evangelista, AF; Moreno, FS; Prata, GB; Reis, RM; Romualdo, GR; Vinken, M, 2020)
"Obesity causes insulin resistance, hyperlipidemia, diabetes, and various diseases throughout the body."	1.46	Daily Coffee Intake Inhibits Pancreatic Beta Cell Damage and Nonalcoholic Steatohepatitis in a Mouse Model of Spontaneous Metabolic Syndrome, Tsumura-Suzuki Obese Diabetic Mice. ( Baba, H; Morimoto, Y; Ogawa, H; Takahashi, T; Tsunematsu, T; Tsuneyama, K; Uehara, H; Watanabe, S, 2017)
"Hyperammonaemia/mild hepatic encephalopathy (HE) can be simulated by the oral administration of a so-called amino acid challenge (AAC)."	1.43	Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine. ( Achermann, P; Amodio, P; Angeli, P; Garrido, M; Montagnese, S; Raduazzo, D; Skorucak, J; Spinelli, G; Turco, M, 2016)
"Caffeine has been noted for its effects on liver inflammation, fibrogenesis, and vasoreactiveness."	1.42	Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats. ( Chang, CC; Chuang, CL; Ho, HL; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Lin, TY; Wang, SS, 2015)
"Hepatitis C is considered the major cause of cirrhosis and hepatocellular carcinoma."	1.42	Caffeine inhibits hepatitis C virus replication in vitro. ( Batista, MN; Braga, AC; Carneiro, BM; Rahal, P, 2015)
"The association of CC with nonalcoholic fatty liver disease (NAFLD) has not been established."	1.38	Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. ( Calcagno, CJ; Harrison, SA; Jones, FJ; Molloy, JW; Torres, DM; Williams, CD, 2012)
"The CBT was applied to 48 patients with NAFLD."	1.37	Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. ( Fung, C; George, J; Katelaris, PH; Ngu, MC; Park, GJ; Seow, F; Wiseman, E, 2011)
"Caffeine intake was compared between patients with mild and advanced liver fibrosis (bridging fibrosis/cirrhosis)."	1.36	Increased caffeine consumption is associated with reduced hepatic fibrosis. ( Everhart, JE; Feld, JJ; Hoofnagle, JH; Kleiner, DE; Liang, TJ; Modi, AA; Park, Y, 2010)
"1."	1.33	Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. ( Chan, ES; Chen, JF; Cronstein, BN; Delano, DL; Desai, A; Fernandez, P; Friedman, SL; Montesinos, MC; Pillinger, MH; Reiss, AB; Schwarzschild, MA; Yee, H, 2006)
"Simplified pharmacokinetic methods have been used to estimate caffeine clearance in subjects with liver disease."	1.30	Evaluation of pharmacokinetic methods used to estimate caffeine clearance and comparison with a Bayesian forecasting method. ( Benowitz, NL; Denaro, CP; Jacob, P, 1998)
"This study attempted to compare the pharmacokinetic parameters of caffeine in patients with chronic liver disease and in normal subjects and to define the two sampling times which are suitable for determining caffeine clearance in these patients."	1.29	Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease. ( Israsena, S; Komolmit, P; Thamaree, S; Tongnopnoua, P; Wittayalertpanya, S, 1996)
" These findings suggest that CA pharmacokinetic parameters can be estimated using a simplified three-point blood sampling procedure following a single oral load and that the serum PX/CA or (PX + TB + TP)/CA ratio in a single blood sample taken 2 or 4 h after dosing provides a useful indicator for the assessment of hepatic drug-oxidizing capacity, N-demethylation, in decompensated liver cirrhosis."	1.28	A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. ( Fukao, K; Ishikawa, A; Iwasaki, Y; Misawa, S; Osada, A; Tanaka, E; Tsuji, K; Yamamoto, Y, 1992)
"In 12 patients with primary idiopathic haemochromatosis absorption and biotransformation were measured by model substances."	1.28	[Resorption and biotransformation of model substances in primary idiopathic hemochromatosis (siderophilia)]. ( Hoffmann, A; Jorke, D; Müller, A; Reinhardt, M; Truckenbrodt, J, 1989)
"001) and no significant differences were observed in the pharmacokinetic data derived from the respective concentration-time curves."	1.28	The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ( Chakraborty, J; Marks, V; Morgan, MY; Scott, NR; Stambuk, D, 1989)
"Caffeine clearance was determined in 13 healthy control subjects and in 13 patients with histologically proven cirrhosis."	1.28	Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. ( Cheng, WS; Cooksley, WG; Halliday, JW; Murphy, TL; Powell, LW; Smith, MT, 1990)
"Caffeine (250 mg) was administered orally to 15 healthy controls and eight patients with cirrhosis."	1.26	Impaired elimination of caffeine in cirrhosis. ( Desmond, PV; Johnson, RF; Patwardhan, RV; Schenker, S, 1980)

Research

Studies (84)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: 12 Weeks

Timeframe	Studies, this research(%)	All Research%
pre-1990	18 (21.43)	18.7374
1990's	23 (27.38)	18.2507
2000's	12 (14.29)	29.6817
2010's	26 (30.95)	24.3611
2020's	5 (5.95)	2.80

Authors	Studies
Duthaler, U	1
Bachmann, F	1
Suenderhauf, C	1
Grandinetti, T	1
Pfefferkorn, F	1
Haschke, M	1
Hruz, P	1
Bouitbir, J	1
Krähenbühl, S	1
Dranoff, JA	3
Romualdo, GR	1
Prata, GB	1
da Silva, TC	1
Evangelista, AF	1
Reis, RM	1
Vinken, M	1
Moreno, FS	1
Cogliati, B	1
Barbisan, LF	3
Sewter, R	1
Heaney, S	1
Patterson, A	1
Yamaguchi, M	2
Dohi, N	1
Ooka, A	1
Saito, SY	2
Ishikawa, T	2
Watanabe, S	1
Takahashi, T	1
Ogawa, H	1
Uehara, H	1
Tsunematsu, T	1
Baba, H	1
Morimoto, Y	1
Tsuneyama, K	1
Nishiyama, R	1
Nakamura, M	1
Todoroki, K	1
Toyo'oka, T	1
Eraky, SM	1
El-Mesery, M	1
El-Karef, A	1
Eissa, LA	1
El-Gayar, AM	1
Chang, CC	2
Chuang, CL	2
Tsai, MH	1
Hsin, IF	2
Hsu, SJ	2
Huang, HC	2
Lee, FY	2
Lee, SD	3
Saab, S	1
Mallam, D	1
Cox, GA	1
Tong, MJ	1
Walton, HB	1
Masterton, GS	1
Hayes, PC	1
Furtado, KS	2
Polletini, J	1
Dias, MC	2
Rodrigues, MA	2
Feld, JJ	2
Lavoie, EG	1
Fausther, M	1
Batista, MN	1
Carneiro, BM	1
Braga, AC	1
Rahal, P	1
Wang, SS	1
Lin, TY	1
Ho, HL	1
Lin, HC	1
Khalaf, N	1
White, D	1
Kanwal, F	1
Ramsey, D	1
Mittal, S	1
Tavakoli-Tabasi, S	1
Kuzniarek, J	1
El-Serag, HB	1
Cuesta-Gragera, A	1
Navarro-Fontestad, C	1
Mangas-Sanjuan, V	1
González-Álvarez, I	1
García-Arieta, A	1
Trocóniz, IF	1
Casabó, VG	1
Bermejo, M	1
Marventano, S	1
Salomone, F	2
Godos, J	1
Pluchinotta, F	1
Del Rio, D	1
Mistretta, A	1
Grosso, G	1
Garrido, M	1
Skorucak, J	1
Raduazzo, D	1
Turco, M	1
Spinelli, G	1
Angeli, P	1
Amodio, P	1
Achermann, P	1
Montagnese, S	1
Jaruvongvanich, V	1
Sanguankeo, A	1
Klomjit, N	1
Upala, S	1
Wijarnpreecha, K	1
Thongprayoon, C	1
Ungprasert, P	1
Galvano, F	1
Li Volti, G	1
Gressner, OA	1
Gao, C	1
Rehbein, K	1
Lahme, B	1
Siluschek, M	1
Berg, T	1
Müller, T	1
Gressner, AM	1
Muriel, P	1
Arauz, J	1
Modi, AA	1
Park, Y	1
Kleiner, DE	1
Everhart, JE	1
Liang, TJ	1
Hoofnagle, JH	1
Park, GJ	2
Wiseman, E	1
George, J	1
Katelaris, PH	2
Seow, F	2
Fung, C	1
Ngu, MC	2
Ong, A	1
Wong, VW	1
Wong, GL	1
Chan, HL	1
Molloy, JW	1
Calcagno, CJ	1
Williams, CD	1
Jones, FJ	1
Torres, DM	1
Harrison, SA	1
Carrieri, MP	1
Sogni, P	1
Cohen, J	1
Loko, MA	1
Winnock, M	1
Spire, B	1
Prado, MG	1
Aguiar E Silva, MA	1
Rivelli, DP	1
Anty, R	1
Marjoux, S	1
Iannelli, A	1
Patouraux, S	1
Schneck, AS	1
Bonnafous, S	1
Gire, C	1
Amzolini, A	1
Ben-Amor, I	1
Saint-Paul, MC	1
Mariné-Barjoan, E	1
Pariente, A	1
Gugenheim, J	1
Gual, P	1
Tran, A	1
MENGUY, R	2
BREGADZE, IL	1
KUZNETSOV, IuV	1
Jodynis-Liebert, J	1
Flieger, J	1
Matuszewska, A	1
Juszczyk, J	1
Jones, DB	1
Lin, BP	1
Le Couteur, DG	1
Higdon, JV	1
Frei, B	1
Chan, ES	1
Montesinos, MC	1
Fernandez, P	1
Desai, A	1
Delano, DL	1
Yee, H	1
Reiss, AB	1
Pillinger, MH	1
Chen, JF	1
Schwarzschild, MA	1
Friedman, SL	1
Cronstein, BN	1
Tarantino, G	1
Conca, P	1
Capone, D	1
Gentile, A	1
Polichetti, G	1
Basile, V	1
Cadden, IS	1
Partovi, N	1
Yoshida, EM	1
Schmilovitz-Weiss, H	1
Niv, Y	1
Pappo, O	1
Halpern, M	1
Sulkes, J	1
Braun, M	1
Barak, N	1
Rotman, Y	1
Cohen, M	1
Waked, A	1
Tur-Kaspa, R	1
Ben-Ari, Z	1
Renner, E	2
Wahländer, A	1
Huguenin, P	1
Wietholtz, H	2
Preisig, R	3
Voegelin, M	1
Arnaud, MJ	1
Bircher, J	2
Desmond, PV	1
Patwardhan, RV	1
Johnson, RF	1
Schenker, S	1
Joeres, R	2
Brachtel, D	2
Gallenkamp, H	1
Hofstetter, G	2
Klinker, H	2
Zilly, W	2
Richter, E	2
Darnót, G	1
Nemesánszky, E	1
Bariska, J	1
Calatayud, O	1
Rodríguez, M	1
Sánchez-Alcaraz, A	1
Ibáñez, P	1
Sharp, DS	1
Benowitz, NL	3
Rodopoulos, N	1
Norman, A	1
Rector, WG	1
Robertson, AD	1
Gilar, M	1
Perlík, F	2
Patzelová, V	1
Farinati, F	1
Dalri, L	1
Rossaro, L	1
Plebani, M	2
Nemetz, L	2
Boccagni, P	1
Bassi, N	1
Naccarato, R	1
Holstege, A	2
Kurz, M	1
Weinbeck, M	1
Gerok, W	2
Denaro, CP	2
Wilson, M	1
Jacob, P	2
Shyu, JK	1
Wang, YJ	1
Lu, RH	1
Lo, KJ	1
Mizuno, A	1
Uematsu, T	1
Gotoh, S	1
Katoh, E	1
Nakashima, M	1
Wittayalertpanya, S	3
Israsena, S	1
Thamaree, S	1
Tongnopnoua, P	1
Komolmit, P	1
Shrestha, R	1
McKinley, C	1
Showalter, R	1
Wilner, K	1
Marsano, L	1
Vivian, B	1
Everson, GT	1
Jover, R	1
Carnicer, F	1
Sánchez-Payá, J	1
Climent, E	1
Sirvent, M	1
Marco, JL	1
Johnson, MA	1
Horak, J	1
Breuel, P	1
Tangkijvanich, P	2
Kusonsolboon, T	1
Thong-Ngam, D	1
Mahachai, V	2
Ariyawongsopon, V	1
Isarasena, S	1
Pucelíková, T	1
Slanar, O	1
Corrao, G	1
Zambon, A	1
Bagnardi, V	1
D'Amicis, A	1
Klatsky, A	1
Gallus, S	1
Tavani, A	1
Negri, E	1
La Vecchia, C	1
Zetterman, RK	1
Leevy, CM	1
Ullrich, D	1
Compagnone, D	1
Münch, B	1
Brandes, A	1
Hille, H	1
Tanaka, E	1
Ishikawa, A	1
Yamamoto, Y	1
Osada, A	1
Tsuji, K	1
Fukao, K	1
Misawa, S	1
Iwasaki, Y	1
McDonagh, JE	1
Nathan, VV	1
Bonavia, IC	1
Moyle, GR	1
Tanner, AR	1
Hartleb, M	1
Nowak, A	1
Becker, A	1
Mańczyk, I	1
Cheng, WS	1
Murphy, TL	1
Smith, MT	1
Cooksley, WG	1
Halliday, JW	1
Powell, LW	1
Varagnolo, M	1
Mussap, M	1
Paleari, CD	1
Burlina, A	1
Hoffmann, A	1
Müller, A	1
Reinhardt, M	1
Truckenbrodt, J	1
Jorke, D	1
Hasegawa, M	1
Yamada, S	1
Hirayama, C	1
Scott, NR	2
Stambuk, D	2
Chakraborty, J	2
Marks, V	2
Morgan, MY	2
Migneco, G	1
Mascarella, A	1
Tripi, S	1
La Cascia, C	1
Navetta, A	1
Staiger, M	1
Haag, K	1
Junggeburth, J	1
Epping, J	1
Wang, T	1
Kleber, G	1
Stellaard, F	1
Paumgartner, G	1
Wahlländer, A	1
Orloff, MJ	1
Chandler, JG	1
Alderman, SJ	1
Keiter, JE	1
Rosen, H	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
In Vivo Determination of Cytochrome P450 Activities in Patients With Liver Cirrhosis[NCT03337945]		48 participants (Actual)	Interventional	2018-04-04	Completed
Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With Hepatitis C and Human Immunodeficiency Virus (Collaboration Inter Cohortes et Centres Cliniques de Sujets Co-infectés Par Les Virus de l'immunodéficence Humaine et de l'hépatit[NCT03324633]		1,850 participants (Actual)	Observational	2005-06-30	Completed
Development of a Breath Test for Monitoring Liver Metabolic Function in Patients With Chronic Liver Disease and Cirrhosis[NCT00244569]	Phase 3	120 participants (Anticipated)	Interventional	2005-09-30	Completed
Neuroplastic Alterations of the Motor Cortex by Caffeine: Differences Between Caffeine and Non-caffeine Users and Influence of Vigilance During Stimulation[NCT04011670]		30 participants (Actual)	Interventional	2019-07-15	Completed
Effect of Coffee and Tea Consumption on Adolescent Weight Control - a Randomized Clinical Trial[NCT05181176]		63 participants (Anticipated)	Interventional	2021-01-01	Recruiting
Cortical Excitability Changes on the Sensorimotor Cortex Induced by Caffeine Consumption: A TMS Study[NCT03720665]		30 participants (Actual)	Interventional	2018-10-01	Completed
Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or [NCT02455167]	Phase 3	9 participants (Actual)	Interventional	2015-05-31	Terminated (stopped due to Study stopped due to low accrual and availability of other treatment options)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome. (NCT02455167)
Timeframe: 12 Weeks

Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: Baseline

Intervention	score on a scale (Mean)
HCV Positive Group	7.25

The Sustained Virologic Response (SVR) in Patients Infected With HCV Genotype 1, Cirrhosis, and Early Clinical Decompensation

Intervention	score on a scale (Mean)
HCV Positive Group	8

"Number of participants who cleared Hepatitis C (HCV) after 12 weeks was collected (HCV RNA level was Not Detected." (NCT02455167)
Timeframe: 12 weeks

Article	Year
Coffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects. American journal of physiology. Gastrointestinal and liver physiology, 2023, 06-01, Volume: 324, Issue:6 Topics: Caffeine; Coffee; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease	2023
Coffee Consumption and the Progression of NAFLD: A Systematic Review. Nutrients, 2021, Jul-12, Volume: 13, Issue:7 Topics: Caffeine; Coffee; Cross-Sectional Studies; Disease Progression; Female; Humans; Liver Cirrhosis; Mal	2021
Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis. Gene expression, 2018, 03-21, Volume: 18, Issue:1 Topics: Animals; Caffeine; Coffee; Humans; Liver; Liver Cirrhosis	2018
Impact of coffee on liver diseases: a systematic review. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:4 Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Caffeine; Carcinoma, Hepatocell	2014
Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clinical nutrition (Edinburgh, Scotland), 2016, Volume: 35, Issue:6 Topics: Caffeine; Coffee; Diet; Humans; Liver Cirrhosis; MEDLINE; Metabolic Syndrome; Non-alcoholic Fatty Li	2016
Effects of caffeine consumption in patients with chronic hepatitis C: A systematic review and meta-analysis. Clinics and research in hepatology and gastroenterology, 2017, Volume: 41, Issue:1 Topics: Administration, Oral; Beverages; Caffeine; Central Nervous System Stimulants; Hepatitis C, Chronic;	2017
Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis. European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:1 Topics: Administration, Oral; Beverages; Caffeine; Central Nervous System Stimulants; Chi-Square Distributio	2017
Molecular Bases Underlying the Hepatoprotective Effects of Coffee. Nutrients, 2017, Jan-23, Volume: 9, Issue:1 Topics: Animals; Caffeine; Chlorogenic Acid; Coffee; Disease Models, Animal; Fatty Liver; Humans; Lipid Meta	2017
Coffee and liver diseases. Fitoterapia, 2010, Volume: 81, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Caffeine; Carcinoma, Hepatocellular; Coffee; Diterpenes;	2010
CURRENT CONCEPTS OF THE ETIOLOGY OF DUODENAL ULCER. The American journal of digestive diseases, 1964, Volume: 9 Topics: Adrenal Cortex Hormones; Aspirin; Caffeine; Duodenal Ulcer; Gastric Juice; Gastric Mucosa; Genetics,	1964
Coffee and health: a review of recent human research. Critical reviews in food science and nutrition, 2006, Volume: 46, Issue:2 Topics: Adult; Caffeine; Carcinoma, Hepatocellular; Cardiovascular Diseases; Child; Chlorogenic Acid; Coffee	2006
Coffee and health: a review of recent human research. Critical reviews in food science and nutrition, 2006, Volume: 46, Issue:2 Topics: Adult; Caffeine; Carcinoma, Hepatocellular; Cardiovascular Diseases; Child; Chlorogenic Acid; Coffee	2006
Coffee and health: a review of recent human research. Critical reviews in food science and nutrition, 2006, Volume: 46, Issue:2 Topics: Adult; Caffeine; Carcinoma, Hepatocellular; Cardiovascular Diseases; Child; Chlorogenic Acid; Coffee	2006
Coffee and health: a review of recent human research. Critical reviews in food science and nutrition, 2006, Volume: 46, Issue:2 Topics: Adult; Caffeine; Carcinoma, Hepatocellular; Cardiovascular Diseases; Child; Chlorogenic Acid; Coffee	2006
Coffee and health: a review of recent human research. Critical reviews in food science and nutrition, 2006, Volume: 46, Issue:2 Topics: Adult; Caffeine; Carcinoma, Hepatocellular; Cardiovascular Diseases; Child; Chlorogenic Acid; Coffee	2006
Coffee and health: a review of recent human research. Critical reviews in food science and nutrition, 2006, Volume: 46, Issue:2 Topics: Adult; Caffeine; Carcinoma, Hepatocellular; Cardiovascular Diseases; Child; Chlorogenic Acid; Coffee	2006
Coffee and health: a review of recent human research. Critical reviews in food science and nutrition, 2006, Volume: 46, Issue:2 Topics: Adult; Caffeine; Carcinoma, Hepatocellular; Cardiovascular Diseases; Child; Chlorogenic Acid; Coffee	2006
Coffee and health: a review of recent human research. Critical reviews in food science and nutrition, 2006, Volume: 46, Issue:2 Topics: Adult; Caffeine; Carcinoma, Hepatocellular; Cardiovascular Diseases; Child; Chlorogenic Acid; Coffee	2006
Coffee and health: a review of recent human research. Critical reviews in food science and nutrition, 2006, Volume: 46, Issue:2 Topics: Adult; Caffeine; Carcinoma, Hepatocellular; Cardiovascular Diseases; Child; Chlorogenic Acid; Coffee	2006
Review article: possible beneficial effects of coffee on liver disease and function. Alimentary pharmacology & therapeutics, 2007, Jul-01, Volume: 26, Issue:1 Topics: Caffeine; Carcinoma, Hepatocellular; Coffee; Humans; Liver Cirrhosis; Liver Neoplasms; Phosphodieste	2007
Immunologic reactivity and alcoholic liver disease. Bulletin of the New York Academy of Medicine, 1975, Volume: 51, Issue:4 Topics: Acetaldehyde; Alcoholism; Antigen-Antibody Reactions; B-Lymphocytes; Caffeine; Chemical and Drug Ind	1975

Article	Year
Serum metabolite/caffeine ratios as a test for liver function. Journal of clinical pharmacology, 2004, Volume: 44, Issue:4 Topics: Adult; Caffeine; Female; Hepatitis, Chronic; Humans; Liver; Liver Cirrhosis; Liver Function Tests; M	2004
[Diagnostic value of the study of caffeine elimination in chronic liver diseases]. Orvosi hetilap, 1995, Apr-30, Volume: 136, Issue:18 Topics: Administration, Oral; Caffeine; Chronic Disease; Female; Gastrointestinal Transit; Hepatitis, Alcoho	1995
Caffeine test assessment for measuring liver function in critically ill patients. Journal of clinical pharmacy and therapeutics, 1995, Volume: 20, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biotransformation; Caffeine; Female; Humans; Intensive C	1995
Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1996, Volume: 57, Issue:5 Topics: Adult; Aged; Caffeine; Humans; Liver; Liver Cirrhosis; Liver Function Tests; Metabolic Clearance Rat	1996
The measurement of caffeine concentration in scalp hair as an indicator of liver function. The Journal of pharmacy and pharmacology, 1996, Volume: 48, Issue:6 Topics: Adult; Caffeine; Female; Gas Chromatography-Mass Spectrometry; Hair; Humans; Indicators and Reagents	1996
The pharmacokinetics of lamivudine in patients with impaired hepatic function. European journal of clinical pharmacology, 1998, Volume: 54, Issue:4 Topics: Adult; Anti-HIV Agents; Caffeine; Female; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged	1998
Caffeine clearance study in hepatocellular carcinoma. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1999, Volume: 82, Issue:3 Topics: Adult; Aged; Caffeine; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Cirrhosis; Liver Func	1999
Short-term effects of branched-chain amino acids on liver function tests in cirrhotic patients. The Southeast Asian journal of tropical medicine and public health, 2000, Volume: 31, Issue:1 Topics: Adult; Alanine Transaminase; Amino Acids, Branched-Chain; Aspartate Aminotransferases; Caffeine; Fem	2000

Article	Year
Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently. Clinical pharmacokinetics, 2022, Volume: 61, Issue:7 Topics: Caffeine; Child; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochr	2022
The combination of coffee compounds attenuates early fibrosis-associated hepatocarcinogenesis in mice: involvement of miRNA profile modulation. The Journal of nutritional biochemistry, 2020, Volume: 85 Topics: Alkaloids; Animals; Anticarcinogenic Agents; Caffeine; Carcinoma, Hepatocellular; Cell Line, Tumor;	2020
Caffeine-induced inversion of prostaglandin E Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 142 Topics: Animals; Caffeine; Cells, Cultured; Cyclic AMP; Dinoprostone; Gene Expression Regulation; Hepatic St	2021
Daily Coffee Intake Inhibits Pancreatic Beta Cell Damage and Nonalcoholic Steatohepatitis in a Mouse Model of Spontaneous Metabolic Syndrome, Tsumura-Suzuki Obese Diabetic Mice. Metabolic syndrome and related disorders, 2017, Volume: 15, Issue:4 Topics: Aging; Animals; Caffeine; Coffee; Diabetes Mellitus, Type 2; Hyperlipidemias; Insulin-Secreting Cell	2017
Caffeine Suppresses the Activation of Hepatic Stellate Cells cAMP-Independently by Antagonizing Adenosine Receptors. Biological & pharmaceutical bulletin, 2017, Volume: 40, Issue:5 Topics: Animals; Caffeine; Cells, Cultured; Chelating Agents; Cyclic AMP; Dose-Response Relationship, Drug;	2017
Silymarin and caffeine combination ameliorates experimentally-induced hepatic fibrosis through down-regulation of LPAR1 expression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 101 Topics: Animals; Antioxidants; Caffeine; Down-Regulation; Drug Therapy, Combination; Gene Expression; Liver	2018
Effects of Caffeine Treatment on Hepatopulmonary Syndrome in Biliary Cirrhotic Rats. International journal of molecular sciences, 2019, Mar-28, Volume: 20, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Caffeine; Disease Models, Animal; Hepato	2019
An epidemiological study of the association of coffee with chronic liver disease. Scottish medical journal, 2013, Volume: 58, Issue:4 Topics: Caffeine; Case-Control Studies; Coffee; Diterpenes; End Stage Liver Disease; Female; Humans; Liver C	2013
Prevention of rat liver fibrosis and carcinogenesis by coffee and caffeine. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2014, Volume: 64 Topics: Animals; Blotting, Western; Caffeine; Carcinogenesis; Coffee; Collagen; Glutathione Transferase; Liv	2014
How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations. Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:2 Topics: Caffeine; Central Nervous System Stimulants; Coffee; Humans; Liver Cirrhosis; Risk Factors; Xanthine	2014
Caffeine inhibits hepatitis C virus replication in vitro. Archives of virology, 2015, Volume: 160, Issue:2 Topics: Antiviral Agents; Apoptosis; Caffeine; Cell Cycle Checkpoints; Cell Line; Cell Survival; Hepacivirus	2015
Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:5 Topics: Animals; Caffeine; Collateral Circulation; Hemodynamics; Hypertension, Portal; Liver Cirrhosis; Port	2015
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:8 Topics: Adult; Aged; Caffeine; Coffee; Cross-Sectional Studies; Feeding Behavior; Female; Hepatitis C, Chron	2015
Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2015, Jun-20, Volume: 73 Topics: Algorithms; Biotransformation; Caffeine; Central Nervous System Stimulants; Computer Simulation; Dos	2015
Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine. Metabolic brain disease, 2016, Volume: 31, Issue:4 Topics: Adult; Brain; Caffeine; Dipeptides; Electroencephalography; Female; Hepatic Encephalopathy; Humans;	2016
Elevated concentrations of 15-deoxy-Delta12,14-prostaglandin J2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor gamma-inducing drugs. Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:5 Topics: Adult; Aged; Asian People; Caffeine; Connective Tissue Growth Factor; Female; Hepatocytes; Humans; L	2009
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:1 Topics: Adolescent; Adult; Aged; Caffeine; Coffee; Diet Surveys; Female; Hepatitis C, Chronic; Humans; Liver	2010
Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Biopsy; Breath Tests; Caffeine; Case-Control S	2011
The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:7 Topics: Adult; Alanine Transaminase; Alcohol Drinking; Body Mass Index; Caffeine; Elasticity Imaging Techniq	2011
Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:2 Topics: Age Factors; Alanine Transaminase; Body Mass Index; Caffeine; Coffee; Fatty Liver; Female; Glycated	2012
Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13). Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:5 Topics: Caffeine; Coffee; Fatty Liver; Female; Humans; Liver; Liver Cirrhosis; Male	2012
Coffee and caffeine protect against liver injury induced by thioacetamide in male Wistar rats. Basic & clinical pharmacology & toxicology, 2012, Volume: 111, Issue:5 Topics: Animals; Caffeine; Caspase 3; Chemical and Drug Induced Liver Injury; Coffee; Collagen; Food Handlin	2012
Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. Journal of hepatology, 2012, Volume: 57, Issue:5 Topics: Adult; Bariatric Surgery; Biopsy; Cacao; Caffeine; Coffee; Cohort Studies; Cola; Comorbidity; Europe	2012
[COMPLICATIONS DURING BROMSULPHALEIN TESTS]. Klinicheskaia meditsina, 1964, Volume: 42 Topics: Caffeine; Calcium; Diphenhydramine; Echinococcosis; Echinococcosis, Hepatic; Hemangiosarcoma; Liver	1964
[ETIOLOGY OF THE DUODENAL ULCER]. Munchener medizinische Wochenschrift (1950), 1964, Mar-27, Volume: 106 Topics: Aspirin; Caffeine; Disease Susceptibility; Duodenal Ulcer; Genetics, Medical; Humans; Hyperparathyro	1964
The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Alimentary pharmacology & therapeutics, 2005, Sep-01, Volume: 22, Issue:5 Topics: Adult; Breath Tests; Caffeine; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Ma	2005
Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. British journal of pharmacology, 2006, Volume: 148, Issue:8 Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Blotting, Western; Caffeine; Carbon Tetrachlorid	2006
Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients. European journal of clinical pharmacology, 2006, Volume: 62, Issue:8 Topics: Adult; Caffeine; Case-Control Studies; Chromatography, High Pressure Liquid; Humans; Liver Cirrhosis	2006
The 13C-caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitis. Journal of clinical gastroenterology, 2008, Volume: 42, Issue:4 Topics: Breath Tests; Caffeine; Carbon Isotopes; Diagnosis, Differential; Fatty Liver; Female; Follow-Up Stu	2008
[Caffeine--an ubiquitous indicator of liver function]. Schweizerische medizinische Wochenschrift, 1983, Aug-09, Volume: 113, Issue:31-32 Topics: Adult; Aged; Caffeine; Female; Galactose; Humans; Liver; Liver Cirrhosis; Liver Diseases; Liver Func	1983
Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test. European journal of clinical pharmacology, 1981, Volume: 21, Issue:1 Topics: Adult; Animals; Breath Tests; Caffeine; Carbon Dioxide; Carbon Radioisotopes; Cytochrome P-450 CYP1A	1981
Impaired elimination of caffeine in cirrhosis. Digestive diseases and sciences, 1980, Volume: 25, Issue:3 Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Aspartate Aminotransferases; Caffeine; Half-Life; Hum	1980
Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology. Zeitschrift fur Gastroenterologie, 1993, Volume: 31 Suppl 2 Topics: Adult; Aged; Caffeine; Diagnosis, Differential; Female; Humans; Liver Cirrhosis; Liver Diseases; Liv	1993
Re: "Alcohol, smoking, coffee, and cirrhosis" and "coffee and serum gamma-glutamyltransferase: a study of self-defense officials in Japan". American journal of epidemiology, 1995, Mar-01, Volume: 141, Issue:5 Topics: Alcohol Drinking; Body Mass Index; Caffeine; Coffee; Confounding Factors, Epidemiologic; Ethanol; ga	1995
Determination of caffeine and its metabolites in urine by high-performance liquid chromatography and capillary electrophoresis. Scandinavian journal of clinical and laboratory investigation, 1994, Volume: 54, Issue:4 Topics: Caffeine; Chromatography, High Pressure Liquid; Electrophoresis; Humans; Liver Cirrhosis	1994
Prevalence and determinants of elevated plasma norepinephrine concentration in compensated cirrhosis. The American journal of gastroenterology, 1994, Volume: 89, Issue:11 Topics: Caffeine; Female; Hemodynamics; Humans; Kidney; Liver; Liver Cirrhosis; Liver Function Tests; Male;	1994
[Determination of caffeine using high-performance liquid chromatography]. Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 1994, Volume: 43, Issue:2 Topics: Caffeine; Chromatography, High Pressure Liquid; Humans; Liver Cirrhosis; Saliva	1994
Serum and salivary caffeine clearance in cirrhosis. Any role in selection for surgery and timing for transplantation? Journal of hepatology, 1993, Volume: 18, Issue:1 Topics: Adult; Aged; Caffeine; Female; Humans; Liver Cirrhosis; Liver Transplantation; Male; Metabolic Clear	1993
Excretion of caffeine and its primary degradation products into bile. Journal of hepatology, 1993, Volume: 17, Issue:1 Topics: Adult; Aged; Bile; Bilirubin; Caffeine; Chromatography, High Pressure Liquid; Female; Humans; Liver	1993
The effect of liver disease on urine caffeine metabolite ratios. Clinical pharmacology and therapeutics, 1996, Volume: 59, Issue:6 Topics: Adult; Analysis of Variance; Caffeine; Female; Humans; Infusions, Intravenous; Liver Cirrhosis; Male	1996
Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease. The Tokai journal of experimental and clinical medicine, 1996, Volume: 21, Issue:4-6 Topics: Adult; Aged; Caffeine; Chronic Disease; Female; Hepatitis; Humans; Liver; Liver Cirrhosis; Liver Dis	1996
Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 1997, Volume: 3, Issue:2 Topics: Administration, Oral; Adult; Aged; Antipyrine; Caffeine; Cholic Acid; Cholic Acids; Disease Progress	1997
Salivary caffeine clearance predicts survival in patients with liver cirrhosis. The American journal of gastroenterology, 1997, Volume: 92, Issue:10 Topics: Aged; Caffeine; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Function Tests; Male; Midd	1997
Evaluation of pharmacokinetic methods used to estimate caffeine clearance and comparison with a Bayesian forecasting method. Therapeutic drug monitoring, 1998, Volume: 20, Issue:1 Topics: Bayes Theorem; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Humans; Least-Squa	1998
[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. Casopis lekaru ceskych, 2001, Feb-01, Volume: 140, Issue:2 Topics: Caffeine; Female; Humans; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Saliva; Theophyl	2001
Coffee, caffeine, and the risk of liver cirrhosis. Annals of epidemiology, 2001, Volume: 11, Issue:7 Topics: Alcohol Drinking; Caffeine; Coffee; Female; Hepatitis, Viral, Human; Humans; Italy; Liver Cirrhosis;	2001
Does coffee protect against liver cirrhosis? Annals of epidemiology, 2002, Volume: 12, Issue:3 Topics: Adult; Aged; Caffeine; Case-Control Studies; Coffee; Female; Hepatitis, Viral, Human; Humans; Italy;	2002
Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations. European journal of clinical pharmacology, 1992, Volume: 43, Issue:2 Topics: Adolescent; Adult; Age Factors; Allopurinol; Caffeine; Child; Cimetidine; Drug Interactions; Female;	1992
A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. International journal of clinical pharmacology, therapy, and toxicology, 1992, Volume: 30, Issue:9 Topics: Adult; Caffeine; Evaluation Studies as Topic; Female; Humans; Liver; Liver Cirrhosis; Male; Methods;	1992
Caffeine clearance by enzyme multiplied immunoassay technique: a simple, inexpensive, and useful indicator of liver function. Gut, 1991, Volume: 32, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Caffeine; Humans; Immunoenzyme Techniques; Liver Cirrhosis; Liver Di	1991
[Effect of smoking on caffeine elimination by the liver in patients with chronic liver diseases]. Polskie Archiwum Medycyny Wewnetrznej, 1990, Volume: 84, Issue:6 Topics: Adolescent; Adult; Aged; Caffeine; Chronic Disease; Fatty Liver, Alcoholic; Hepatitis, Chronic; Huma	1990
Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clinical pharmacology and therapeutics, 1990, Volume: 47, Issue:4 Topics: Administration, Oral; Adult; Aged; Biological Availability; Caffeine; Dose-Response Relationship, Dr	1990
Caffeine as indicator of metabolic functions of microsomal liver enzymes. Clinica chimica acta; international journal of clinical chemistry, 1989, Jul-31, Volume: 183, Issue:1 Topics: Adult; Caffeine; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Female; Half-Life;	1989
[Resorption and biotransformation of model substances in primary idiopathic hemochromatosis (siderophilia)]. Gastroenterologisches Journal : Organ der Gesellschaft fur Gastroenterologie der DDR, 1989, Volume: 49, Issue:3 Topics: Adult; Biotransformation; Caffeine; Dipyrone; Hemochromatosis; Humans; Intestinal Absorption; Liver;	1989
Fasting plasma caffeine level in cirrhotic patients: relation to plasma levels of catecholamines and renin activity. Hepatology (Baltimore, Md.), 1989, Volume: 10, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Caffeine; Catecholamines; Epinephrine; Fasting; Female;	1989
The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. British journal of clinical pharmacology, 1989, Volume: 27, Issue:2 Topics: Adult; Aged; Caffeine; Female; Half-Life; Humans; Liver Cirrhosis; Liver Function Tests; Male; Middl	1989
[Cytolytic episodes during cirrhosis]. La Clinica terapeutica, 1986, Jul-31, Volume: 118, Issue:2 Topics: Antipyrine; Anxiety Disorders; Barbiturates; Caffeine; Cholestasis; Drug Therapy, Combination; Femal	1986
Correlation of caffeine elimination and Child's classification in liver cirrhosis. Klinische Wochenschrift, 1989, Jan-04, Volume: 67, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Caffeine; Chromatography, High Pressure Liquid	1989
[One point determination of oral caffeine clearance in patients with liver diseases]. Zeitschrift fur Gastroenterologie, 1988, Volume: 26, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Caffeine; Female; Hepatitis B; Hep	1988
Caffeine clearance and biotransformation in patients with chronic liver disease. Clinical science (London, England : 1979), 1988, Volume: 74, Issue:4 Topics: Adult; Aged; Biotransformation; Caffeine; Chronic Disease; Female; Humans; Liver Cirrhosis; Male; Mi	1988
Caffeine elimination: a test of liver function. Klinische Wochenschrift, 1985, Nov-04, Volume: 63, Issue:21 Topics: Adult; Aged; Caffeine; Female; Humans; Liver Cirrhosis; Liver Diseases; Liver Function Tests; Male;	1985
Fasting plasma caffeine concentration. A guide to the severity of chronic liver disease. Scandinavian journal of gastroenterology, 1985, Volume: 20, Issue:9 Topics: Adult; Caffeine; Chronic Disease; Fasting; Female; Humans; Liver Cirrhosis; Liver Diseases; Liver Fu	1985
Gastric secretion and peptic ulcer following portacaval shunt in man. Annals of surgery, 1969, Volume: 170, Issue:4 Topics: Adult; Aged; Caffeine; Gastric Juice; Glycols; Histamine; Humans; Liver Cirrhosis; Liver Function Te	1969

caffeine and Cirrhosis, Liver